Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-04-06
2010-06-22
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S416000
Reexamination Certificate
active
07741358
ABSTRACT:
The invention relates to an orthorhombic crystal form of compound trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz [2,3:6,7]oxepino[4,5-c]pyrrole (Z)-2-butenedioate, to methods for the preparation of this crystal form and to pharmaceutical compositions comprising an orthorhombic crystal form.
REFERENCES:
patent: 4145434 (1979-03-01), van der Burg
patent: 4154386 (1979-05-01), Kawada
patent: 4481205 (1984-11-01), Von Bebenburg et al.
patent: 4786735 (1988-11-01), Grayboes et al.
patent: 5534522 (1996-07-01), Ando et al.
patent: 5763476 (1998-06-01), Delbressine et al.
patent: 2006/0084692 (2006-04-01), Wong et al.
patent: 2006/0229352 (2006-10-01), Kemperman
patent: WO 95/23600 (1995-09-01), None
patent: WO 99/32108 (1999-07-01), None
patent: WO 2004/110437 (2004-12-01), None
Mortimer, Ann. Expert Opinion on Investigational Drugs, 2004, 13(4), 315-329.
Vervoort el al. Journal of Chromatography A, 1994, 678(1) 1-15.
Broekkamp et al. Drug Research, 1990, 40(5), 544-49.
DeBoer et al. Drug Research, 1990, 40(5), 550-554.
Room et al. European Journal of Pharmacology, 1991, 205, 233-40.
European Search Report for Application No. EP 06 11 2332 dated Aug. 14, 2006.
Vader, J. et al., “The Syntheses of Radiolabelled Org 5222 and Its Main Metabolite Org 30526,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 34, No. 9 (1994) pp. 845-869.
De Boer, Th. et al., Org-5222 “Antipsychotic Dopamine D2Receptor Antagonist 5-HT2Receptor Antagonist,” Drugs of the Future, vol. 18, No. 12 (1993) pp. 1117-1123.
Funke, C. W. et al., “Physico-chemical Properties and Stability of trans-5-Chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrolidine Maleate,” Arzneim.-Forsch./Drug Res., vol. 40, No. 5 (1990) pp. 536-539.
Devlin Gerard
Fischer H. Eric
Jarrell Noble
N.V. Organon
Wilson James O
LandOfFree
Crystal form of asenapine maleate does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystal form of asenapine maleate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystal form of asenapine maleate will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4182436